Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2018
MSD’s anti-viral Prevymis fails to win NICE backing
4 July 2018 - MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus reactivation and ...
Posted by Michael Wonder on 04 Jul 2018
Two of three US pharma companies receive Independence Day treat from NICE
4 July 2018 - NICE has released its final appraisal determinations for Tesaro, Pfizer and BMS cancer medicines. ...
Posted by Michael Wonder on 01 Jul 2018
NICE rejects ocrelizumab (Ocrevus) for primary progressive MS in England and Wales
29 June 2018 - The MS Trust is very disappointed that NICE is unable to recommend ocrelizumab as an NHS treatment ...
Posted by Michael Wonder on 28 Jun 2018
NICE backs Roche’s Alecensa
28 June 2018 - Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, ...
Posted by Michael Wonder on 22 Jun 2018
Sanofi’s Dupixent approved for routine NHS use
22 June 2018 - Adults with moderate to severe atopic dermatitis are a step closer to being able to routinely ...
Posted by Michael Wonder on 22 Jun 2018
NICE backs Ocrevus but primary-progressive group kept waiting
22 June 2018 - NICE published a positive final appraisal determination on Friday for Ocrevus (ocrelizumab) to treat people living ...
Posted by Michael Wonder on 16 Jun 2018
Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance
15 June 2018 - Women with a type of early breast cancer may not benefit from continuing or starting a ...
Posted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate ...
Posted by Michael Wonder on 07 Jun 2018
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer
6 June 2018 - The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (Zytiga) ...
Posted by Michael Wonder on 06 Jun 2018
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
6 June 2018 - It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely ...
Posted by Michael Wonder on 06 Jun 2018
Life-extending lung cancer drug will be more widely available on the NHS after NICE review
6 June 2018 - NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new ...
Posted by Michael Wonder on 05 Jun 2018
NICE rules against first-line use of Ipsen’s Cabometyx
5 June 2018 - NICE has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on ...
Posted by Michael Wonder on 31 May 2018
Pfizer's Xalkori makes it onto Cancer Drugs Fund
31 May 2018 - NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung ...
Posted by Michael Wonder on 27 May 2018
NICE issues decision on Mylotarg, Besponsa for leukaemia
25 May 2018 - NICE has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid ...
Posted by Michael Wonder on 23 May 2018
NICE says no to Chiesi’s rare disease drug
23 May 2018 - England’s cost effectiveness watchdog NICE has published draft guidance not recommending Chiesi’s enzyme replacement therapy Lamzede ...